Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.